

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Obesity; metabolic syndrome	Complement component 1q subcomponent (C1Q); complement component 1q subcomponent A chain (C1QA)	<p>Mouse studies suggest inhibiting C1Q signaling could help prevent obesity-associated metabolic impairments and metabolic syndrome. In women who were obese and in mice fed a high-fat diet, complement-factor activation in adipose tissue was increased compared with lean controls. In mice, <i>C1qa</i> deficiency prevented high-fat diet-induced impairments in glucose homeostasis and decreased both hepatic steatosis and insulin resistance compared with no <i>C1qa</i> deficiency. Next steps could include developing C1QA-specific inhibitors and evaluating them in obesity models.</p> <p>SciBX 6(31); doi:10.1038/scibx.2013.827 Published online Aug. 15, 2013</p>	Patent and licensing status unavailable	<p>Hillian, A.D. <i>et al. J. Biol. Chem.</i>; published online June 20, 2013; doi:10.1074/jbc.M113.465674 Contact: Laura Nagy, Cleveland Clinic Cleveland, Ohio e-mail: nagyL3@ccf.org</p>